Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 801–900 of 1,052
Li, X., Chen, Y., Cao, X., Feng, W., Chen, Y., & Zhang, J. (2025) · ACS Nano · doi:10.1021/acsnano.4c16585 · Cited by 35
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1649394 · Cited by 29
Sivashanmugarajah, A. S., Fulcher, J., SULLIVAN, D. R., Elam, M. B., Jenkins, A. J., & KEECH, A. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14429 · Cited by 28
Lian, Z., Perrard, X. D., Peng, X., Raya, J. L., Hernandez, A. A., Johnson, C. G., Lagor, W. R., Pownall, H. J., Hoogeveen, R. C., Simon, S. I., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313078 · Cited by 29
Self-citationCarrasco, R. A., Ramirez, M. C., Nes, K., Schuster, A., Aguayo, R., Morales, M., Ramos, C., Hasson, D., Sotomayor, C. G., Henriquez, P., et al. (2020) · Trials · doi:10.1186/s13063-019-3963-6 · Cited by 27
Lambadiari, V., Korakas, E., & Tsimihodimos, V. (2020) · Nutrients · doi:10.3390/nu12082204 · Cited by 32
Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 44
Self-citationJia, X., Gao, F., Pickett, J. K., Al Rifai, M., Birnbaum, Y., Nambi, V., Virani, S. S., & Ballantyne, C. M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07204-z · Cited by 27
Self-citationA randomized trial of icosapent ethyl in ambulatory patients with COVID-19
Kosmopoulos, A., Bhatt, D. L., Meglis, G., Verma, R., Pan, Y., Quan, A., Teoh, H., Verma, M., Jiao, L., Wang, R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103040 · Cited by 28
Self-citationSecondary Prevention of Cardiovascular Disease in Women: Closing the Gap
Thakkar, A., Agarwala, A., & Michos, E. D. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.24 · Cited by 31
Mozaffarian, D., Maki, K. C., Bays, H. E., Aguilera, F., Gould, G., Hegele, R. A., Moriarty, P. M., Robinson, J. G., Shi, P., Tur, J. F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.41898 · Cited by 37
Bäck, M., Xhaard, C., Rouget, R., Thuillier, Q., Plunde, O., Larsson, S. C., Girerd, N., Ferreira, J. P., Boivin, J., Bozec, E., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac016 · Cited by 29
Molecular Pharmacology of Inflammation Resolution in Atherosclerosis
Kotlyarov, S. N., & Котлярова, А. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094808 · Cited by 34
Omega-3 and cardiovascular prevention – Is this still a choice?
Ruscica, M., Sirtori, C. R., Carugo, S., Calder, P. C., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106342 · Cited by 30
Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?
Bhattacharya, P., Kanagasooriyan, R., & Subramanian, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102283 · Cited by 33
Yokoi, K., Yanagimoto, K., & Hayamizu, K. (2022) · Nutrients · doi:10.3390/nu14194136 · Cited by 32
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
Dicklin, M. R., Anthony, J. C., Winters, B., & Maki, K. C. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.03.015 · Cited by 35
Amigó, N., Akinkuolie, A. O., Chiuve, S. E., Correig, X., Cook, N. R., & Mora, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014963 · Cited by 29
Shabbir, A., Rathod, K. S., Khambata, R. S., & Ahluwalia, A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023229 · Cited by 30
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression
Pan, G., Cavalli, M., Carlsson, B., Skrtic, S., Kumar, C., & Wadelius, C. (2020) · iScience · doi:10.1016/j.isci.2019.100808 · Cited by 26
Effects of Omega-3 Fatty Acid Supplements on Arrhythmias
Parish, S., Mafham, M., Offer, A., Barton, J., Wallendszus, K., Stevens, W., Buck, G., Haynes, R., Collins, R., Bowman, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044165 · Cited by 26
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 31
Zimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae090 · Cited by 29
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“%) or at high risk for developing CVD (HR = 0.75; 95 %CI: 0.68-0.83; p < 0.001) [87].”
BackgroundInfluentialHypercholesterolemia and inflammation—Cooperative cardiovascular risk factors
Gallo, A., Goff, W. L., Santos, R. D., Fichtner, I., Carugo, S., Corsini, A., Sirtori, C. R., & Ruscica, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14326 · Cited by 32
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray, K. K., Linnebjerg, H., Michael, L. F., Shen, X. P., Ma, X., Lim, S., Zhen, Y., Dudek, H., Abrams, M., Saxena, U. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.005 · Cited by 32
Lumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Lucchinetti, E., Lou, P., Wawrzyniak, P., Wawrzyniak, M., Scharl, M. M., Holtzhauer, G., Krämer, S. D., Hersberger, M., Rogler, G., & Zaugg, M. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201901270 · Cited by 30
Climax, J., Newsome, P. N., Hamza, M., Weissbach, M., Coughlan, D., Sattar, N., McGuire, D. K., & Bhatt, D. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016334 · Cited by 26
Self-citationCardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus
Cardoso, R. N., Dudum, R., Ferraro, R., Bittencourt, M. S., Blankstein, R., Blaha, M. J., Nasir, K., Rajagopalan, S., Michos, E. D., Blumenthal, R. S., et al. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.011365 · Cited by 28
Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease
Golledge, J., & Drovandi, A. D. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62778 · Cited by 28
Dietary Control of Inflammation and Resolution
Sears, B., & Saha, A. K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.709435 · Cited by 34
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Tzanaki, I., Agouridis, A. P., & Kostapanos, M. S. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.119 · Cited by 31
Ruggenenti, P. L., Cortinovis, M., Trillini, M., Parvanova, A. I., Abbate, M., Satriano, C., Salvetti, F., Bossi, A. C., Trevisan, R., Perna, A., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109804 · Cited by 27
Extrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure
Rao, A., Gupta, A., Kain, V., & Halade, G. V. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00276.2023 · Cited by 28
Lee, S., Cha, J., Choi, W., Lee, W. S., Jeong, J., Choi, S., Cho, Y.-H., Park, W., Yoon, C.-H., Lee, Y., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2222 · Cited by 26
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
Bowman, G. L., Silbert, L. C., Dodge, H. H., Lahna, D. L., Hagen, K., Murchison, C., Howieson, D. B., Kaye, J. A., Quinn, J. F., & Shinto, L. H. (2019) · Nutrients · doi:10.3390/nu11040735 · Cited by 27
Mortensen, M. B., Blaha, M. J., & Nordestgaard, B. G. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4759 · Cited by 27
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle Jr, R. T., Juliano, R. A., Jiao, L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa118 · Cited by 25
Self-citationRemnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 27
Akivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 29
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 30
Lewis, E., Steenson, S., Haslam, R. P., McDonald, E., Sharman, M., Τράκα, Μ., Stanton, A. V., Napier, J. A., Sweeting, A., Saleh, R. N. M., et al. (2025) · Nutrition Research Reviews · doi:10.1017/s0954422425100127 · Cited by 43
Antiperovitch, P., Iliescu, E. A., & Chan, B. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.02.017 · Cited by 26
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Specialized pro-resolving mediators in diabetes: novel therapeutic strategies
Brennan, E. P., Mohan, M., Andrews, D. C., Bose, M., & Kantharidis, P. (2019) · Clinical Science · doi:10.1042/cs20190067 · Cited by 30
Mangiacapra, F., Buono, M. G. D., Abbate, A., Gori, T., Barbato, E., Montone, R. A., Crea, F., & Niccoli, G. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.02.009 · Cited by 27
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Vors, C., Allaire, J., Mejía, S. B., Khan, T. A., Sievenpiper, J. L., & Lamarche, B. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa086 · Cited by 29
Kim, K., Song, Y., Oh, T. J., Choi, S. H., & Jang, H. C. (2020) · Nutrients · doi:10.3390/nu12113365 · Cited by 28
Cainzos‐Achirica, M., Bittencourt, M. S., Osei, A. D., Haque, W. Z., Bhatt, D. L., Blumenthal, R. S., Blankstein, R., Ray, K. K., Blaha, M. J., & Nasir, K. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.10.016 · Cited by 25
Self-citationSobrino, A., Walker, M. E., Colas, R. A., & Dalli, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242543 · Cited by 30
Khan, S. U., Khan, M. U., Virani, S. S., Khan, M. S., Khan, M. Z., Rashid, M. O., Kalra, A., Alkhouli, M. A., Blaha, M. J., Blumenthal, R. S., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa093 · Cited by 34
Canakinumab for Secondary Prevention of Coronary Artery Disease
Ortega‐Paz, L., Capodanno, D., & Angiolillo, D. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0211 · Cited by 29
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 32
Durstenfeld, M. S., & Hsue, P. Y. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000681 · Cited by 27
Petersen, K. S., Kris‐Etherton, P. M., McCabe, G. P., Raman, G., Miller, J. W., & Maki, K. C. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab045 · Cited by 28
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02966-4 · Cited by 27
Keeley, E. C., Li, H. J., Cogle, C. R., Handberg, E. M., Merz, C. N. B., & Pepine, C. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.09.015 · Cited by 25
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
Salazar, J. J., Pírela, D., Nava, M., Castro, A. V., Angarita, L., Parra, H., Durán‐Agüero, S., Rojas-Gómez, D. M., Galbán, N., Áñez, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063133 · Cited by 28
Timmerman, N., Waissi, F., Dekker, M., de Borst, G. J., van Bennekom, J., de Winter, R. J., Hilvo, M., Jylhä, A., Pasterkamp, G., de Kleijn, D. P. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09225-6 · Cited by 27
Yang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
Chang, Y., Eom, S., Kim, M.-J., & Song, T. (2023) · Medicina · doi:10.3390/medicina59040776 · Cited by 31
Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia
Cheung, B., Sikand, G., Dineen, E. H., Malik, S., & El-Farra, A. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103414 · Cited by 30
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
Omega-3 Fatty Acids and Atrial Fibrillation
Curfman, G. (2021) · JAMA · doi:10.1001/jama.2021.2909 · Cited by 27
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 26
Cardiovascular Risk Reduction with Icosapent Ethyl
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902165 · Cited by 24
Cainzos-Achirica, M., Quispe, R., Dudum, R., Greenland, P., Lloyd-Jones, D., Rana, J. S., Lima, J. A. C., Doria de Vasconcellos, H., Joshi, P. H., Khera, A., et al. (2022) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2021.10.017 · Cited by 24
Giubilato, S., Lucà, F., Abrignani, M. G., Gatto, L., Rao, C. M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185989 · Cited by 33
A rapid action plan to improve diagnosis and management of lipodystrophy syndromes
Fourman, L. T., Lima, J. G., Simha, V., Cappa, M., Al-Yaarubi, S., Montenegro, R. M., Akıncı, B., & Santini, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383318 · Cited by 25
Omega-3 Fatty Acids and Arrhythmias
Marcus, M. D., & Link, M. S. (2024) · Circulation · doi:10.1161/circulationaha.123.065769 · Cited by 31
Estándares SEA 2019 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Ascaso, J. F., Valdivielso, P., Velilla, T. A., Brea, Á., Calmarza, P., Cebollada, J., et al. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.03.004 · Cited by 61
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future
Perez-Martinez, P., Katsiki, N., & Mikhailidis, D. P. (2019) · Angiology · doi:10.1177/0003319719842005 · Cited by 25
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 26
Singh, M., McEvoy, J. W., Khan, S. U., Wood, D., Graham, I. M., Blumenthal, R. S., Mishra, A., & Michos, E. D. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.011 · Cited by 33
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 32
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24
Self-citationThe year in cardiovascular medicine 2020: epidemiology and prevention
Estruch, R., Ruilope, L. M., & Cosentino, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1062 · Cited by 27
Pal, A., Sun, S., Armstrong, M., Manke, J., Reisdorph, N., Adams, V. R., Kennedy, A. J., Zu, Y., Moustaïd‐Moussa, N., Carroll, I. M., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159059 · Cited by 28
Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 27
The Effect of Diet on Cardiovascular Disease, Heart Disease, and Blood Vessels
Tada, H., Takamura, M., & Kawashiri, M.-A. (2022) · Nutrients · doi:10.3390/nu14020246 · Cited by 28
Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin
Hoshino, T., Ishizuka, K., Toi, S., Mizuno, T., Nishimura, A., Wako, S., Takahashi, S., & Kitagawa, K. (2022) · Neurology · doi:10.1212/wnl.0000000000200112 · Cited by 29
Szili‐Török, T., Sokooti, S., Osté, M. C. J., Neto, A. W. G., Dullaart, R. P. F., Bakker, S. J. L., & Tietge, U. J. F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01475-y · Cited by 27
Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage
Shoamanesh, A., & Selim, M. H. (2022) · Stroke · doi:10.1161/strokeaha.122.036889 · Cited by 29
Halminen, J., Sattar, N. A., Rawshani, A., Eliasson, B., Eeg‐Olofsson, K., Bhatt, D. L., & Rawshani, A. (2022) · Diabetes Care · doi:10.2337/dc22-0926 · Cited by 26
Self-citationNew algorithms for treating homozygous familial hypercholesterolemia
Tromp, T. R., & Cuchel, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000853 · Cited by 26
Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy
Rosendael, S. E. V., van den Hoogen, I. J., Lin, F. Y.-H., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K. M., Choi, J. H., Conte, E., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.10.017 · Cited by 29
Costanzo, A. D., Indolfi, C., Sorrentino, S., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411739 · Cited by 27
Zec, M. M., Schutte, A. E., Ricci, C., Baumgartner, J., Kruger, I. M., & Smuts, C. M. (2019) · Foods · doi:10.3390/foods8090394 · Cited by 28
Sabouret, P. F., Galati, G., Angoulvant, D., Андреевна, Г. О., Castelletti, S., Pathak, A., Metra, M., & Margonato, A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa051 · Cited by 24
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23
“Consequently, the efficacy of icosapent ethyl could be upward biased and thus overestimate the cost-effectiveness of icosapent ethyl [5, 43].”
BackgroundPalacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. D. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.027 · Cited by 29
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 29
Vijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 26
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.